Quay Pharma’s Deeside plant successfully re-inspected

Published: 9-May-2011
Manufacturing Packaging Research & Development

Adds an ion chromatography system and plans new GMP manufacturing suites

UK pharmaceutical outsourcing specialist Quay Pharma has invested in a variety of new equipment to enhance its support services for clients following last year’s move to its new plant in Deeside, North Wales.

The facility has also undergone a successful re-inspection by the MHRA (the UK Medicines and Healthcare products Regulatory Agency), confirming that the company is fully compliant with good manufacturing practices (GMP).

The new equipment includes an ion chromatography system, which has been added to Quay's analytical development instrumentation portfolio to support two new projects requiring this specialist capability.

The first of the projects concerned is for a French biopharmaceutical company, which is seeking to develop products for severe neurological disorders. The instrumentation will be used with pulsed amperometry electrochemical detection to monitor extremely low levels of sugars in a combination drug product.

The second project, for a new UK pharmaceutical company, involves measurement of a cationic drug (API) and its degradation products by conductivity detection.

In addition, the Formulation Development department, which specialises in the development of solid dosages, creams, liquids and gels, has been expanded to include a new pilot facility alongside the laboratory.

This pilot lab will offer the capability for early phase work in standard techniques such as tabletting, coating and capsule filling, as well as more complex processes such as extrusion spheronisation and semi-solid and liquid filling and banding of capsules. It will assist in the scale-up of production prior to full manufacture as well as providing proof of concept studies and samples for pharmacokinetic (PK) studies.

As well as the investment in new equipment, Quay is also planning to introduce new GMP manufacturing suites, with work on these expected to start in the autumn.

‘The move to the new premises has effectively quadrupled the available space for these important departments and will allow us to provide a greatly enhanced range of services to both existing and new customers,’ said Quay Pharma’s chief executive Mike Rubinstein.

‘At the same time, we are delighted that our commitment to the highest quality and best practice has been confirmed by our successful MHRA inspection.’

  • Companies:
  • Quay Pharma
See more

You may also like

Drug Delivery

SGS Quay Pharma receives Queen’s Award for industry

Read more
Leading pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for Enterprise

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  2. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets
  3. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

SGS Quay Pharma receives Queen’s Award for industry

Leading pharmaceutical contract development and manufacturing organisation (CDMO) SGS Quay Pharma has received its Queen’s Award for Enterprise
Research & Development

Quay Pharma to supply promising cancer drug for trial

Quay Pharma has reached an agreement with Redx Pharma to manufacture Redx’s breakthrough cancer treatment drug
Research & Development

Quay Pharma awarded Eurostars funding for oncology project

Joins a consortium that will work with Hercules Pharmaceuticals to develop a new therapy for breast cancer
Regulatory

Quay Pharma GMP manufacturing suites gain MHRA approval

Pharma outsourcing specialist is now able to make larger non-sterile product batches to support clinical trials and small-scale commercial manufacture
Manufacturing

Quay Pharma gains Commercial Licence to broaden its contract manufacturing services at its UK facilities

The expanded capabilities will allow the firm to support its clients through all stages of drug development and clinical supply
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Interview: Voyage of discovery

A degree in science does not automatically lead to a job in a lab. Maireadh Pedersen described to Hilary Ayshford how her meandering career path took her from biochemistry to finance, from engineering to business development and then to running Quay Pharma
Manufacturing

KTP funding supports oral dosage development at Quay Pharma

The firm will work in partnership with Professor Peter Williams at Glyndwyr University in Wrexham, UK
Subscribe now